Cargando…
Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533258/ https://www.ncbi.nlm.nih.gov/pubmed/34680127 http://dx.doi.org/10.3390/biom11101495 |
_version_ | 1784587269383913472 |
---|---|
author | Castaldelli-Maia, João M. Malbergier, André de Oliveira, Adriana B. P. Amaral, Ricardo A. Negrão, André B. Gonçalves, Priscila D. Ventriglio, Antonio de Berardis, Domenico de Antonio, Juliana Firigato, Isabela Gattás, Gilka J. F. de Toledo Gonçalves, Fernanda |
author_facet | Castaldelli-Maia, João M. Malbergier, André de Oliveira, Adriana B. P. Amaral, Ricardo A. Negrão, André B. Gonçalves, Priscila D. Ventriglio, Antonio de Berardis, Domenico de Antonio, Juliana Firigato, Isabela Gattás, Gilka J. F. de Toledo Gonçalves, Fernanda |
author_sort | Castaldelli-Maia, João M. |
collection | PubMed |
description | Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study. |
format | Online Article Text |
id | pubmed-8533258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85332582021-10-23 Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder Castaldelli-Maia, João M. Malbergier, André de Oliveira, Adriana B. P. Amaral, Ricardo A. Negrão, André B. Gonçalves, Priscila D. Ventriglio, Antonio de Berardis, Domenico de Antonio, Juliana Firigato, Isabela Gattás, Gilka J. F. de Toledo Gonçalves, Fernanda Biomolecules Article Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study. MDPI 2021-10-10 /pmc/articles/PMC8533258/ /pubmed/34680127 http://dx.doi.org/10.3390/biom11101495 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Castaldelli-Maia, João M. Malbergier, André de Oliveira, Adriana B. P. Amaral, Ricardo A. Negrão, André B. Gonçalves, Priscila D. Ventriglio, Antonio de Berardis, Domenico de Antonio, Juliana Firigato, Isabela Gattás, Gilka J. F. de Toledo Gonçalves, Fernanda Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title | Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title_full | Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title_fullStr | Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title_full_unstemmed | Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title_short | Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder |
title_sort | exploring the role of alcohol metabolizing genotypes in a 12-week clinical trial of naltrexone for alcohol use disorder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533258/ https://www.ncbi.nlm.nih.gov/pubmed/34680127 http://dx.doi.org/10.3390/biom11101495 |
work_keys_str_mv | AT castaldellimaiajoaom exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT malbergierandre exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT deoliveiraadrianabp exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT amaralricardoa exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT negraoandreb exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT goncalvespriscilad exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT ventriglioantonio exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT deberardisdomenico exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT deantoniojuliana exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT firigatoisabela exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT gattasgilkajf exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder AT detoledogoncalvesfernanda exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder |